January 23, 2018 / 5:24 PM / in 3 months

BRIEF-Biofrontera: 12-Month Follow-Up Results Of Phase III Trial For Daylight PDT

Jan 23 (Reuters) - BIOFRONTERA AG:

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES 12-MONTH FOLLOW-UP RESULTS OF THE PHASE III TRIAL FOR DAYLIGHT PDT

* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS A CLEAR TREND TOWARDS IMPROVED EFFICACY

* OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS LOWER RECURRENCE RATES FOR AMELUZ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below